Literature DB >> 20852653

Twists and turns on the way to progress in metastatic castrate-resistant prostate cancer.

Oliver Sartor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20852653      PMCID： PMC3739067          DOI： 10.1038/aja.2010.113

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  7 in total

1.  The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

Authors:  W B Coley
Journal:  Clin Orthop Relat Res       Date:  1991-01       Impact factor: 4.176

2.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

3.  Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

Authors:  Kim N Chi; Sebastien J Hotte; Evan Y Yu; Dongsheng Tu; Bernhard J Eigl; Ian Tannock; Fred Saad; Scott North; Jean Powers; Martin E Gleave; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2010-08-23       Impact factor: 44.544

4.  Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

Authors:  Nicholas D James; Armelle Caty; Michael Borre; Bernard A Zonnenberg; Philippe Beuzeboc; Thomas Morris; De Phung; Nancy A Dawson
Journal:  Eur Urol       Date:  2008-11-29       Impact factor: 20.096

5.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

Authors:  Cora N Sternberg; Daniel P Petrylak; Oliver Sartor; J Alfred Witjes; Tomasz Demkow; Jean-Marc Ferrero; Jean-Christophe Eymard; Silvia Falcon; Fabio Calabrò; Nicholas James; Istvan Bodrogi; Peter Harper; Manfred Wirth; William Berry; Michael E Petrone; Thomas J McKearn; Mojtaba Noursalehi; Martine George; Marcel Rozencweig
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

7.  A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

Authors:  Michael A Carducci; Fred Saad; Per-Anders Abrahamsson; David P Dearnaley; Claude C Schulman; Scott A North; Darryl J Sleep; Jeffrey D Isaacson; Joel B Nelson
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.